



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 10/826136

TO: Robert J Balls
Location: 4d78 / 4c70
Art Unit: 1625
Tuesday, January 31, 2006

Case Serial Number: 10/826136

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: James Balls Examiner #: 82049 Date: 31 Jan 2006
Art Unit: 1625 Phone Number: 2- Serial Number: 10/821071382
Location (Bldg/Room#): 4D78 (Mailbox #): 4C70 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): Robert Hofgen

Earliest Priority Date: _____

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

STAFF USE ONLY		Type of Search	Vendors and cost where applicable	
Searcher: <u>NOBLIS</u>		<input type="checkbox"/> NA Sequence (#)	<input checked="" type="checkbox"/> STN	<input type="checkbox"/> Dialog
Searcher Phone #:		<input type="checkbox"/> AA Sequence (#)	<input type="checkbox"/> Questel/Orbit	<input type="checkbox"/> Lexis/Nexis
Searcher Location:		<input checked="" type="checkbox"/> Structure (#)	<input type="checkbox"/> Westlaw	<input type="checkbox"/> WWW/Internet
Date Searcher Picked Up:	<u>1/31/06</u>	<input checked="" type="checkbox"/> Bibliographic	<input type="checkbox"/> In-house sequence systems	
Date Completed:	<u>1/31/06</u>	<input type="checkbox"/> Litigation	<input type="checkbox"/> Commercial	<input type="checkbox"/> Score/Length
Searcher Prep & Review Time:	<u>6</u>	<input type="checkbox"/> Fulltext	<input type="checkbox"/> Interference	<input type="checkbox"/> SPDI
Online Time:	<u>71</u>	<input type="checkbox"/> Other	<input type="checkbox"/> Other (specify)	

=> b reg
FILE 'REGISTRY' ENTERED AT 13:08:09 ON 31 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2006 HIGHEST RN 873057-98-8
DICTIONARY FILE UPDATES: 30 JAN 2006 HIGHEST RN 873057-98-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>



=> d que sta 117
L15 STR



VAR G1=N/10
VAR G2=C/N/10
VAR G3=NH/23
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
CONNECT IS E1 RC AT 22
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L17 52 SEA FILE=REGISTRY SSS FUL L15100.0% PROCESSED 55 ITERATIONS 52 ANSWERS
SEARCH TIME: 00.00.01=> d que sta 125
L23 STR

VAR G1=N/10
VAR G2=C/N/10
VAR G4=7/8
VAR G5=15/16/17
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24


STEREO ATTRIBUTES: NONE
L25 98 SEA FILE=REGISTRY SSS FUL L23100.0% PROCESSED 199771 ITERATIONS 98 ANSWERS
SEARCH TIME: 00.00.13=> d que sta 137
L23 STR

VAR G1=N/10
VAR G2=C/N/10
VAR G4=7/8
VAR G5=15/16/17
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L25 98 SEA FILE=REGISTRY SSS FUL L23
L34 STR

VAR G1=N/10

VAR G4=7/8

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 27

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L36 101 SEA FILE=REGISTRY SSS FUL L34
L37 3 SEA FILE=REGISTRY ABB=ON PLU=ON L36 NOT L25

=> b hcap

FILE 'HCAPLUS' ENTERED AT 13:08:46 ON 31 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Jan 2006 VOL 144 ISS 6

FILE LAST UPDATED: 30 Jan 2006 (20060130/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d all hitstr l41 1-2

L41 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1037098 HCAPLUS
 DN 143:347150
 ED Entered STN: 28 Sep 2005
 TI Preparation of pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
 IN Salom, Barbara; D'Anello, Matteo; Brasca, Maria Gabriella; Giordano, Patrizia; Martina, Katia; Angelucci, Francesco; Brookfield, Frederick

Arthur; Trigg, William John; Boyd, Edward Andrew; Larard, Jonathan Anthony
 PA Pharmacia Italia S.p.A., Italy
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC C07D-0471/04; A61K-0031/437
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63


FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005063746	A1	20050714	2004WO-XC14674	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO2005063746	A1	20050714	2004WO-EP14674	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2003GB-0030043	A	20031224		
2004WO-EP14674	A	20041223		


CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063746	IC	C07D-0471/04; A61K-0031/437
	IPCI	C07D0471-04 [ICM]; A61K0031-437 [ICS]
	ECLA	C07D471/04+221B+209B
WO2005063746	IPCI	C07D0471-04 [ICM, 7]; A61K0031-437 [ICS, 7]
	ECLA	C07D471/04+221B+209B

GI



I



II

AB The title compds. [I; R = Ra, CORa, CONRaRb, SO2Ra, CO2Ra; R1 = NRcRd, ORc; Ra, Rb, Rc and Rd = H, alkyl, cycloalkyl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed.

Preparation of compds. I is described in eleven synthetic examples. E.g., a multi-step synthesis of II, starting from 5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid and isoamylamine-bearing resin, was given. The compds. I or compns. comprising them may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Also disclosed is a process under SPS conditions for preparing the compds. I and chemical libraries comprising a plurality of them. This is a Part IV of I-IV series.

ST pyrrolopyridine prepn protein kinase inhibitor antitumor antiproliferative antiviral; Alzheimer disease pyrrolopyridine prepn; neurodegenerative disorder pyrrolopyridine prepn; combinatorial library pyrrolopyridine prepn protein kinase inhibitor

IT Sarcoma
(Kaposi's, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Antiarteriosclerotics
(antiatherosclerotics, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Prostate gland, disease
(benign hyperplasia, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hyperplasia
(benign prostatic, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, disease
(degeneration, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Lung, disease
(fibrosis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Thyroid gland, neoplasm
(follicle cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Chemotherapy
Radiotherapy
(for augmentation of; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Inflammation

Kidney, disease
(glomerulonephritis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Transplant and Transplantation
(host-vs.-graft reaction; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(lymphoid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(mesenchymal, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(metastasis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Endocrine system, neoplasm
Neoplasm
(multiple endocrine neoplasia, treating familial adenomatosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(myeloid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Mesenchyme
(neoplasm, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, neoplasm
(neurofibromatosis type 1, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Bone, neoplasm
Sarcoma
(osteosarcoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Digestive tract, neoplasm
(polyposis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Antitumor agents
Antiviral agents
Cell proliferation
Combination chemotherapy
Combinatorial chemistry
Combinatorial library
Human
Immunomodulators
Immunosuppressants
Nervous system agents
Solid phase synthesis
Transplant rejection
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Fibrosis
(pulmonary, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Artery, disease
(restenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Testis, neoplasm
(seminoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Blood vessel
(smooth muscle, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
(squamous cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

kinase inhibitors)
 IT Artery, disease
 (stenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Carcinoma
 (teratocarcinoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Alopecia
 (treating or preventing radiotherapy-induced or chemotherapy-induced alopecia; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Atherosclerosis
 (treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Alzheimer's disease
 Antiarthritics
 Arthritis
 Autoimmune disease
 Carcinoma
 Melanoma
 Nervous system, neoplasm
 Psoriasis
 (treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Infection
 (viral, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Skin, disease
 (xanthoma, treating keratoanthoma; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Skin, disease
 (xeroderma pigmentosum, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT 372092-80-3, Protein kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT 865839-17-4P 865839-18-5P 865839-19-6P 865839-20-9P 865839-21-0P
 865839-22-1P 865839-23-2P 865839-24-3P 865839-25-4P 865839-26-5P
 865839-27-6P 865839-28-7P 865839-29-8P 865839-30-1P 865839-31-2P
 865839-32-3P 865839-33-4P 865839-34-5P 865839-35-6P 865839-36-7P
 865839-37-8P 865839-38-9P 865839-39-0P 865839-40-3P 865839-41-4P
 865839-42-5P 865839-43-6P 865839-44-7P 865839-45-8P 865839-46-9P
 865839-47-0P 865839-48-1P 865839-51-6P 865839-52-7P 865839-53-8P
 865839-54-9P 865839-55-0P 865839-56-1P 865839-57-2P 865839-58-3P
 865839-59-4P 865839-60-7P 865839-61-8P 865839-62-9P 865839-63-0P
 865839-64-1P 865839-65-2P 865839-66-3P 865839-67-4P 865839-68-5P
 865839-69-6P 865839-70-9P 865839-71-0P 865839-72-1P 865839-73-2P
 865839-74-3P 865839-75-4P 865839-76-5P 865839-77-6P 865839-78-7P
 865839-79-8P 865839-80-1P 865839-81-2P 865839-82-3P 865839-83-4P
 865839-84-5P 865839-85-6P 865839-86-7P 865839-87-8P 865839-88-9P
 865839-89-0P 865839-91-4P 865839-92-5P 865839-93-6P 865839-94-7P
 865839-95-8P 865839-97-0P 865840-00-2P 865840-03-5P 865840-04-6P
 865840-05-7P 865840-08-0P 865840-11-5P 865840-12-6P 865840-13-7P
 865840-14-8P 865840-15-9P 865840-16-0P 865840-17-1P 865840-18-2P
 865840-19-3P 865840-20-6P 865840-21-7P 865840-22-8P 865840-23-9P
 865840-24-0P 865840-25-1P 865840-26-2P 865840-27-3P 865840-28-4P
 865840-29-5P 865840-30-8P 865840-31-9P 865840-32-0P 865840-33-1P
 865840-34-2P 865840-35-3P 865840-36-4P 865840-38-6P 865840-39-7P
 865840-40-0P 865840-41-1P 865840-42-2P 865840-43-3P 865840-44-4P
 865840-45-5P 865840-46-6P 865840-47-7P 865840-48-8P 865840-49-9P
 865840-50-2P 865840-51-3P 865840-52-4P 865840-53-5P 865840-54-6P
 865840-55-7P 865840-56-8P 865840-57-9P 865840-58-0P 865840-59-1P
 865840-60-4P 865840-61-5P 865840-62-6P 865840-63-7P 865840-64-8P
 865840-65-9P 865840-66-0P 865840-67-1P 865840-68-2P 865840-69-3P
 865840-70-6P 865840-71-7P 865840-72-8P 865840-73-9P 865840-74-0P

865840-75-1P	865840-76-2P	865840-78-4P	865840-79-5P	865840-80-8P
865840-81-9P	865840-82-0P	865840-83-1P	865840-84-2P	865840-85-3P
865840-86-4P	865840-87-5P	865840-88-6P	865840-89-7P	865840-90-0P
865840-91-1P	865840-92-2P	865840-93-3P	865840-94-4P	865840-95-5P
865840-96-6P	865840-97-7P	865840-98-8P	865840-99-9P	865841-00-5P
865841-01-6P	865841-02-7P	865841-03-8P	865841-04-9P	865841-05-0P
865841-06-1P	865841-07-2P	865841-08-3P	865841-09-4P	865841-10-7P
865841-11-8P	865841-12-9P	865841-14-1P	865841-15-2P	865841-16-3P
865841-17-4P	865841-18-5P	865841-19-6P	865841-20-9P	865841-21-0P
865841-22-1P	865841-23-2P	865841-24-3P	865841-25-4P	865841-26-5P
865841-27-6P	865841-28-7P	865841-29-8P	865841-30-1P	865841-31-2P
865841-32-3P	865841-33-4P	865841-34-5P	865841-35-6P	865841-36-7P
865841-37-8P	865841-38-9P	865841-39-0P	865841-40-3P	865841-41-4P
865841-42-5P	865841-43-6P	865841-44-7P	865841-45-8P	865841-46-9P
865841-48-1P	865841-49-2P	865841-50-5P	865841-51-6P	865841-52-7P
865841-53-8P	865841-54-9P	865841-55-0P	865841-56-1P	865841-57-2P
865841-58-3P	865841-59-4P	865841-60-7P	865841-61-8P	865841-62-9P
865841-63-0P	865841-64-1P	865841-65-2P	865841-66-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT	865841-67-4P	865841-68-5P	865841-69-6P	865841-70-9P	865841-71-0P
	865841-72-1P	865841-73-2P	865841-74-3P	865841-75-4P	865841-76-5P
	865841-77-6P	865841-78-7P	865841-79-8P	865841-80-1P	865841-81-2P
	865841-82-3P	865841-83-4P	865841-84-5P	865841-86-7P	865841-87-8P
	865841-88-9P	865841-89-0P	865841-90-3P	865841-91-4P	865841-92-5P
	865841-93-6P	865841-94-7P	865841-95-8P	865841-96-9P	865841-97-0P
	865841-98-1P	865841-99-2P	865842-00-8P	865842-01-9P	865842-02-0P
	865842-03-1P	865842-04-2P	865842-05-3P	865842-06-4P	865842-07-5P
	865842-08-6P	865842-09-7P	865842-10-0P	865842-11-1P	865842-12-2P
	865842-13-3P	865842-14-4P	865842-15-5P	865842-16-6P	865842-17-7P
	865842-18-8P	865842-19-9P	865842-20-2P	865842-21-3P	865842-22-4P
	865842-23-5P	865842-24-6P	865842-25-7P	865842-26-8P	865842-27-9P
	865842-28-0P	865842-29-1P	865842-30-4P	865842-31-5P	865842-32-6P
	865842-33-7P	865842-34-8P	865842-35-9P	865842-36-0P	865842-37-1P
	865842-38-2P	865842-39-3P	865842-40-6P	865842-41-7P	865842-42-8P
	865842-43-9P	865842-44-0P	865842-45-1P	865842-46-2P	865842-47-3P
	865842-48-4P	865842-49-5P	865842-50-8P	865842-51-9P	865842-52-0P
	865842-53-1P	865842-54-2P	865842-55-3P	865842-56-4P	865842-57-5P
	865842-58-6P	865842-59-7P	865842-60-0P	865842-61-1P	865842-62-2P
	865842-63-3P	865842-64-4P	865842-65-5P	865842-66-6P	865842-67-7P
	865842-68-8P	865842-69-9P	865842-70-2P	865842-71-3P	865842-72-4P
	865842-73-5P	865842-74-6P	865842-75-7P	865842-76-8P	865842-77-9P
	865842-78-0P	865842-79-1P	865842-80-4P	865842-81-5P	865842-82-6P
	865842-83-7P	865842-84-8P	865842-85-9P	865842-86-0P	865842-87-1P
	865842-88-2P	865842-89-3P	865842-90-6P	865842-91-7P	865842-92-8P
	865842-93-9P	865842-94-0P	865842-95-1P	865842-96-2P	865842-97-3P
	865842-98-4P	865842-99-5P	865843-00-1P	865843-01-2P	865843-02-3P
	865843-03-4P	865843-04-5P	865843-05-6P	865843-06-7P	865843-07-8P
	865843-08-9P	865843-09-0P	865843-10-3P	865843-11-4P	865843-12-5P
	865843-13-6P	865843-14-7P	865843-15-8P	865843-16-9P	865843-17-0P
	865843-18-1P	865843-19-2P	865843-20-5P	865843-21-6P	865843-22-7P
	865843-23-8P	865843-25-0P	865843-26-1P	865843-27-2P	865843-28-3P
	865843-29-4P	865843-30-7P	865843-31-8P	865843-32-9P	865843-33-0P
	865843-34-1P	865843-35-2P	865843-36-3P	865843-37-4P	865843-38-5P
	865843-39-6P	865843-40-9P	865843-41-0P	865843-42-1P	865843-43-2P
	865843-44-3P	865843-45-4P	865843-46-5P	865843-47-6P	865843-48-7P
	865843-49-8P	865843-50-1P	865843-51-2P	865843-52-3P	865843-53-4P
	865843-54-5P	865843-55-6P	865843-56-7P	865843-57-8P	865843-58-9P
	865843-59-0P	865843-60-3P	865843-61-4P	865843-62-5P	865843-63-6P
	865843-64-7P	865843-65-8P	865843-66-9P	865843-67-0P	865843-68-1P
	865843-69-2P	865843-70-5P	865843-71-6P	865843-72-7P	865843-73-8P
	865843-74-9P	865843-75-0P	865843-76-1P	865843-77-2P	865843-78-3P
	865843-79-4P	865843-80-7P	865843-81-8P	865843-82-9P	865843-83-0P
	865843-84-1P	865843-85-2P	865843-86-3P	865843-87-4P	865843-88-5P

865843-89-6P 865843-90-9P 865843-91-0P 865843-92-1P 865843-93-2P
 865843-94-3P 865843-95-4P 865843-96-5P 865843-97-6P 865843-98-7P
 865843-99-8P 865844-00-4P 865844-02-6P 865844-03-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865844-04-8P 865844-05-9P 865844-06-0P 865844-07-1P 865844-08-2P
 865844-09-3P 865844-10-6P 865844-11-7P 865844-12-8P 865844-13-9P
 865844-14-0P 865844-15-1P 865844-16-2P 865844-17-3P 865844-18-4P
 865844-19-5P 865844-20-8P 865844-21-9P 865844-22-0P 865844-23-1P
 865844-24-2P 865844-25-3P 865844-26-4P 865844-27-5P 865844-28-6P
 865844-29-7P 865844-30-0P 865844-31-1P 865844-32-2P 865844-33-3P
 865844-34-4P 865844-35-5P 865844-36-6P 865844-37-7P 865844-38-8P
 865844-39-9P 865844-40-2P 865844-41-3P 865844-42-4P 865844-43-5P
 865844-44-6P 865844-45-7P 865844-46-8P 865844-47-9P 865844-48-0P
 865844-49-1P 865844-50-4P 865844-51-5P 865844-52-6P 865844-53-7P
 865844-54-8P 865844-55-9P 865844-56-0P 865844-57-1P 865844-58-2P
 865844-59-3P 865844-60-6P 865844-61-7P 865844-62-8P 865844-63-9P
 865844-64-0P 865844-65-1P 865844-66-2P 865844-67-3P 865844-68-4P
 865844-69-5P 865844-70-8P 865844-71-9P 865844-72-0P 865844-73-1P
 865844-74-2P 865844-75-3P 865844-76-4P 865844-77-5P 865844-78-6P
 865844-79-7P 865844-80-0P 865844-81-1P 865844-82-2P 865844-83-3P
 865844-84-4P 865844-85-5P 865844-86-6P 865844-87-7P 865844-88-8P
 865844-89-9P 865844-90-2P 865844-91-3P 865844-92-4P 865844-93-5P
 865844-94-6P 865844-95-7P 865844-96-8P 865844-97-9P 865844-98-0P
 865844-99-1P 865845-00-7P 865845-01-8P 865845-02-9P 865845-03-0P
 865845-04-1P 865845-05-2P 865845-06-3P 865845-07-4P 865845-08-5P
 865845-09-6P 865845-10-9P 865845-11-0P 865845-12-1P 865845-13-2P
 865845-14-3P 865845-15-4P 865845-16-5P 865845-17-6P 865845-18-7P
 865845-19-8P 865845-20-1P 865845-21-2P 865845-22-3P 865845-23-4P
 865845-24-5P 865845-25-6P 865845-26-7P 865845-27-8P 865845-28-9P
 865845-29-0P 865845-30-3P 865845-31-4P 865845-32-5P 865845-33-6P
 865845-34-7P 865845-35-8P 865845-36-9P 865845-37-0P 865845-38-1P
 865845-39-2P 865845-40-5P 865845-41-6P 865845-42-7P 865845-43-8P
 865845-44-9P 865845-45-0P 865845-46-1P 865845-47-2P 865845-48-3P
 865845-49-4P 865845-50-7P 865845-51-8P 865845-52-9P 865845-53-0P
 865845-54-1P 865845-55-2P 865845-56-3P 865845-57-4P 865845-58-5P
 865845-59-6P 865845-60-9P 865845-61-0P 865845-62-1P 865845-63-2P
 865845-64-3P 865845-65-4P 865845-66-5P 865845-67-6P 865845-68-7P
 865845-69-8P 865845-70-1P 865845-71-2P 865845-72-3P 865845-73-4P
 865845-74-5P 865845-75-6P 865845-76-7P 865845-77-8P 865845-78-9P
 865845-79-0P 865845-80-3P 865845-81-4P 865845-82-5P 865845-83-6P
 865845-84-7P 865845-85-8P 865845-86-9P 865845-87-0P 865845-88-1P
 865845-89-2P 865845-90-5P 865845-91-6P 865845-92-7P 865845-93-8P
 865845-94-9P 865845-95-0P 865845-96-1P 865845-97-2P 865845-98-3P
 865845-99-4P 865846-00-0P 865846-01-1P 865846-02-2P 865846-03-3P
 865846-04-4P 865846-05-5P 865846-06-6P 865846-07-7P 865846-08-8P
 865846-09-9P 865846-10-2P 865846-11-3P 865846-12-4P 865846-13-5P
 865846-14-6P 865846-15-7P 865846-16-8P 865846-17-9P 865846-18-0P
 865846-19-1P 865846-20-4P 865846-21-5P 865846-22-6P 865846-23-7P
 865846-24-8P 865846-25-9P 865846-26-0P 865846-27-1P 865846-28-2P
 865846-29-3P 865846-30-6P 865846-31-7P 865846-32-8P 865846-33-9P
 865846-34-0P 865846-35-1P 865846-36-2P 865846-37-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865846-38-4P 865846-39-5P 865846-40-8P 865846-41-9P 865846-42-0P
 865846-43-1P 865846-44-2P 865846-45-3P 865846-46-4P 865846-47-5P
 865846-48-6P 865846-49-7P 865846-50-0P 865846-51-1P 865846-52-2P
 865846-53-3P 865846-54-4P 865846-55-5P 865846-56-6P 865846-57-7P
 865846-58-8P 865846-59-9P 865846-60-2P 865846-61-3P 865846-62-4P
 865846-63-5P 865846-64-6P 865846-65-7P 865846-66-8P 865846-67-9P
 865846-68-0P 865846-69-1P 865846-70-4P 865846-71-5P 865846-72-6P
 865846-73-7P 865846-74-8P 865846-75-9P 865846-76-0P 865846-77-1P

865846-78-2P	865846-79-3P	865846-80-6P	865846-81-7P	865846-82-8P
865846-83-9P	865846-84-0P	865846-85-1P	865846-86-2P	865846-87-3P
865846-88-4P	865846-89-5P	865846-90-8P	865846-91-9P	865846-92-0P
865846-93-1P	865846-94-2P	865846-95-3P	865846-96-4P	865846-97-5P
865846-98-6P	865846-99-7P	865847-00-3P	865847-01-4P	865847-02-5P
865847-03-6P	865847-04-7P	865847-05-8P	865847-06-9P	865847-07-0P
865847-08-1P	865847-09-2P	865847-10-5P	865847-11-6P	865847-12-7P
865847-13-8P	865847-14-9P	865847-15-0P	865847-16-1P	865847-17-2P
865847-18-3P	865847-19-4P	865847-20-7P	865847-21-8P	865847-22-9P
865847-23-0P	865847-24-1P	865847-25-2P	865847-26-3P	865847-27-4P
865847-28-5P	865847-29-6P	865847-30-9P	865847-31-0P	865847-32-1P
865847-33-2P	865847-34-3P	865847-35-4P	865847-36-5P	865847-37-6P
865847-38-7P	865847-39-8P	865847-40-1P	865847-41-2P	865847-42-3P
865847-43-4P	865847-44-5P	865847-45-6P	865847-46-7P	865847-47-8P
865847-48-9P	865847-49-0P	865847-50-3P	865847-51-4P	865847-52-5P
865847-53-6P	865847-54-7P	865847-55-8P	865847-56-9P	865847-57-0P
865847-58-1P	865847-59-2P	865847-60-5P	865847-61-6P	865847-62-7P
865847-63-8P	865847-64-9P	865847-65-0P	865847-66-1P	865847-67-2P
865847-68-3P	865847-69-4P	865847-70-7P	865847-71-8P	865847-72-9P
865847-73-0P	865847-74-1P	865847-75-2P	865847-76-3P	865847-77-4P
865847-78-5P	865847-79-6P	865847-80-9P	865847-81-0P	865847-82-1P
865847-83-2P	865847-84-3P	865847-85-4P	865847-86-5P	865847-87-6P
865847-88-7P	865847-89-8P	865847-90-1P	865847-91-2P	865847-92-3P
865847-93-4P	865847-94-5P	865847-95-6P	865847-96-7P	865847-97-8P
865847-98-9P	865847-99-0P	865848-00-6P	865848-01-7P	865848-02-8P
865848-03-9P	865848-04-0P	865848-05-1P	865848-06-2P	865848-07-3P
865848-08-4P	865848-09-5P	865848-10-8P	865848-11-9P	865848-12-0P
865848-13-1P	865848-14-2P	865848-15-3P	865848-16-4P	865848-17-5P
865848-18-6P	865848-19-7P	865848-20-0P	865848-21-1P	865848-22-2P
865848-23-3P	865848-24-4P	865848-25-5P	865848-26-6P	865848-27-7P
865848-28-8P	865848-29-9P	865848-30-2P	865848-31-3P	865848-32-4P
865848-33-5P	865848-34-6P	865848-35-7P	865848-36-8P	865848-37-9P
865848-40-4P	865848-41-5P	865848-44-8P	865848-45-9P	865848-46-0P
865848-47-1P	865848-48-2P	865848-49-3P	865848-50-6P	865848-51-7P
865848-52-8P	865848-53-9P	865848-54-0P	865848-55-1P	865848-56-2P
865848-57-3P	865848-58-4P	865848-59-5P	865848-60-8P	865848-61-9P
865848-62-0P	865848-63-1P	865848-64-2P	865848-65-3P	865848-66-4P
865848-67-5P	865848-68-6P	865848-69-7P	865848-70-0P	865848-71-1P
865848-72-2P	865848-73-3P	865848-74-4P	865848-75-5P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT	865848-76-6P	865848-77-7P	865848-78-8P	865848-79-9P	865848-80-2P
	865848-81-3P	865848-82-4P	865848-83-5P	865848-84-6P	865848-85-7P
	865848-86-8P	865848-87-9P	865848-88-0P	865848-89-1P	865848-90-4P
	865848-91-5P	865848-92-6P	865848-93-7P	865848-94-8P	865848-95-9P
	865848-96-0P	865848-97-1P	865848-98-2P	865848-99-3P	865849-00-9P
	865849-01-0P	865849-02-1P	865849-03-2P	865849-04-3P	865849-05-4P
	865849-06-5P	865849-07-6P	865849-08-7P	865849-09-8P	865849-10-1P
	865849-11-2P	865849-12-3P	865849-13-4P	865849-14-5P	865849-15-6P
	865849-16-7P	865849-17-8P	865849-18-9P	865849-19-0P	865849-20-3P
	865849-21-4P	865849-22-5P	865849-23-6P	865849-24-7P	865849-25-8P
	865849-26-9P	865849-27-0P	865849-28-1P	865849-29-2P	865849-30-5P
	865849-31-6P	865849-32-7P	865849-33-8P	865849-34-9P	865849-35-0P
	865849-36-1P	865849-37-2P	865849-38-3P	865849-39-4P	865849-40-7P
	865849-41-8P	865849-42-9P	865849-43-0P	865849-44-1P	865849-45-2P
	865849-46-3P	865849-47-4P	865849-48-5P	865849-49-6P	865849-50-9P
	865849-51-0P	865849-52-1P	865849-53-2P	865849-54-3P	865849-55-4P
	865849-56-5P	865849-57-6P	865849-58-7P	865849-59-8P	865849-60-1P
	865849-61-2P	865849-62-3P	865849-63-4P	865849-64-5P	865849-65-6P
	865849-66-7P	865849-67-8P	865849-68-9P	865849-69-0P	865849-70-3P
	865849-71-4P	865849-72-5P	865849-73-6P	865849-74-7P	865849-75-8P
	865849-76-9P	865849-77-0P	865849-78-1P	865849-79-2P	865849-80-5P
	865849-81-6P	865849-82-7P	865849-83-8P	865849-84-9P	865849-85-0P
	865849-86-1P	865849-87-2P	865849-88-3P	865849-89-4P	865849-90-7P

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG



US2005209269 A1 20050922 2004US-0020794 20041223
 PRAI 2003GB-0030042 A 20031224

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2005063747	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM, 7]; A61K0031-437 [ICS, 7]; A61P0035-00 [ICS, 7]
US2005209269	ECLA	C07D471/04+221B+209B
	IPCI	A61K0031-4745 [ICM, 7]; C07D0471-02 [ICS, 7]
	NCL	514/300.000
	ECLA	C07D471/04+221B+209B

OS MARPAT 143:133351
 GI



AB The title compds. [I; R = Ra, CORa, CONRaRb, SO2Ra, CO2Ra; R1 = NRcRd, ORc; Ra, Rb, Rc and Rd = H, alkyl, cycloalkyl, etc.; R2 = alkyl, alkenyl, cycloalkyl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in ten examples. E.g., a multi-step synthesis of II, starting from 5-nitro-1H-pyrazolo[2,3-b]pyridine-3-carboxylic acid and 4-fluorobenzylamine-bearing resin, was given. The compds. I or compns. may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Also disclosed is a process under SPS conditions for preparing the compds. I and chemical libraries comprising a plurality of them.

ST pyrrolopyridine prepn protein kinase inhibitor antitumor antiproliferative antiviral; Alzheimer disease pyrrolopyridine prepn; neurodegenerative disorder pyrrolopyridine prepn; combinatorial library pyrrolopyridine prepn protein kinase inhibitor

IT Sarcoma
 (Kaposi's, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Antiarteriosclerotics

(antiatherosclerotics, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Prostate gland, disease
(benign hyperplasia, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hyperplasia
(benign prostatic, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, disease
(degeneration, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Lung, disease
(fibrosis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Thyroid gland, neoplasm
(follicle cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Chemotherapy
Radiotherapy
(for augmentation of; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Inflammation
Kidney, disease
(glomerulonephritis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Transplant and Transplantation
(host-vs.-graft reaction; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(lymphoid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(mesenchymal, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(metastasis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Endocrine system, neoplasm
Neoplasm
(multiple endocrine neoplasia, treating familial adenomatosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(myeloid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Mesenchyme
(neoplasm, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, neoplasm
(neurofibromatosis type 1, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Bone, neoplasm
Sarcoma
(osteosarcoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Digestive tract, neoplasm
(polyposis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Antitumor agents
Antiviral agents
Cell proliferation
Combinatorial chemistry
Combinatorial library

Human
 Immunomodulators
 Immunosuppressants
 Nervous system agents
 Transplant rejection
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Fibrosis
 (pulmonary, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Artery, disease
 (restenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Testis, neoplasm
 (seminoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Blood vessel
 (smooth muscle, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Carcinoma
 (squamous cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Artery, disease
 (stenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Carcinoma
 (teratocarcinoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Alopecia
 (treating or preventing radiotherapy-induced or chemotherapy-induced alopecia; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Atherosclerosis
 (treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Alzheimer's disease
 Antiarthritics
 Arthritis
 Autoimmune disease
 Carcinoma
 Melanoma
 Nervous system, neoplasm
 Psoriasis
 (treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Infection
 (viral, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Skin, disease
 (xanthoma, treating keratoanthoma; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT Skin, disease
 (xeroderma pigmentosum, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT 858340-95-1P 858340-96-2P 858340-97-3P 858340-98-4P 858340-99-5P
 RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 IT 858339-48-7P 858339-49-8P 858339-50-1P 858339-51-2P
 858339-52-3P 858339-53-4P 858339-54-5P 858339-56-7P
 858339-57-8P 858339-58-9P 858339-59-0P
 858339-60-3P 858339-61-4P 858339-62-5P 858339-63-6P
 858339-64-7P 858339-65-8P 858339-66-9P 858339-67-0P
 858339-68-1P 858339-69-2P 858339-70-5P 858339-71-6P

858339-72-7P 858339-73-8P 858339-74-9P
 858339-75-0P 858339-76-1P 858339-77-2P 858339-78-3P
 858339-79-4P 858339-80-7P 858339-81-8P 858339-82-9P
 858339-83-0P 858339-84-1P 858339-85-2P 858339-86-3P
 858339-87-4P 858339-88-5P 858339-89-6P 858339-90-9P
 858339-91-0P 858339-92-1P 858339-93-2P 858339-94-3P
 858339-95-4P 858339-96-5P 858339-97-6P 858339-98-7P
 858339-99-8P 858340-00-8P 858340-01-9P 858340-02-0P
 858340-03-1P 858340-04-2P 858340-05-3P
 858340-06-4P 858340-07-5P 858340-08-6P 858340-09-7P
 858340-10-0P 858340-11-1P 858340-12-2P 858340-13-3P
 858340-14-4P 858340-15-5P 858340-16-6P
 858340-17-7P 858340-18-8P 858340-19-9P
 858340-20-2P 858340-21-3P 858340-22-4P 858340-23-5P
 858340-24-6P 858340-25-7P 858340-26-8P 858340-27-9P 858340-28-0P
 858340-29-1P 858340-30-4P 858340-31-5P 858340-32-6P 858340-33-7P
 858340-34-8P 858340-35-9P 858340-36-0P 858340-37-1P 858340-38-2P
 858340-39-3P 858340-40-6P 858340-41-7P 858340-42-8P 858340-43-9P
 858340-44-0P 858340-45-1P 858340-46-2P 858340-47-3P 858340-48-4P
 858340-49-5P 858340-50-8P 858340-51-9P 858340-52-0P 858340-53-1P
 858340-54-2P 858340-55-3P 858340-56-4P 858340-57-5P 858340-58-6P
 858340-59-7P 858340-60-0P 858340-61-1P 858340-62-2P 858340-63-3P
 858340-64-4P 858340-65-5P 858340-66-6P 858340-67-7P 858340-68-8P
 858340-69-9P 858340-70-2P 858340-71-3P 858340-72-4P 858340-73-5P
 858340-74-6P 858340-75-7P 858340-76-8P 858340-77-9P 858340-78-0P
 858340-79-1P 858340-80-4P 858340-81-5P 858340-82-6P 858340-83-7P
 858340-84-8P 858340-85-9P 858340-86-0P
858340-87-1P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 110-89-4, Piperidine, reactions 111-36-4, Butyl isocyanate 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 140-75-0, 4-Fluorobenzylamine 1885-14-9, Phenyl chloroformate
 RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-93-9P 858340-94-0P
 RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 71-23-8, n-Propanol, reactions 34461-00-2, Sodium nitromalonaldehyde 245064-81-7 858341-00-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-88-2P 858340-89-3P 858340-90-6P 858340-91-7P 858340-92-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Graczyk, P; WO--03082868 A 2003 HCAPLUS
 (2) Longo, A; WO--0198299 A 2001 HCAPLUS


IT 858339-48-7P 858339-49-8P 858339-52-3P
 858339-53-4P 858339-57-8P 858339-58-9P
 858339-59-0P 858339-60-3P 858339-65-8P
 858339-66-9P 858339-69-2P 858339-70-5P
 858339-73-8P 858339-74-9P 858339-75-0P
 858339-76-1P 858339-81-8P 858339-82-9P
 858339-85-2P 858339-86-3P 858339-89-6P
 858339-90-9P 858339-91-0P 858339-92-1P
 858339-96-5P 858339-97-6P 858340-00-8P
 858340-01-9P 858340-04-2P 858340-05-3P

858340-06-4P 858340-07-5P 858340-12-2P
 858340-13-3P 858340-15-5P 858340-16-6P
 858340-17-7P 858340-18-8P 858340-19-9P
 858340-20-2P 858340-85-9P 858340-86-0P
 858340-87-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)


RN 858339-48-7 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-49-8 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-52-3 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(3-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-53-4 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(3-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-57-8 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-1-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-58-9 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-59-0 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-1-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858339-60-3 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858339-65-8 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-66-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-69-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-70-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-73-8 HCAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-74-9 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-75-0 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-methylphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-76-1 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-methylphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-81-8 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-82-9 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-85-2 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-86-3 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-89-6 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-5-[(methylsulfonyl)amino]-N-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-90-9 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(phenylmethyl)amino]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-91-0 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-92-1 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-96-5 HCPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-97-6 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-00-8 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-01-9 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-04-2 HCAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[(methylsulfonyl)amino]-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858340-05-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-06-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-methylphenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858340-07-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-methylphenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-12-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-13-3 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(cyclohexylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 858340-15-5 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-(phenylmethyl)-5-[(cyclohexylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 858340-16-6 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(cyclohexylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 858340-17-7 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-[(1-methyl-1-phenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-18-8 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-19-9 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-20-2 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 858340-85-9 HCPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-86-0 HCPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[[[4-(acetylamino)phenyl]sulfonyl]amino]-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-87-1 HCPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[[[(butylamino)carbonyl]amino]-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



=> d all fhitstr l41 3-4

L41 ANSWER 3 OF 4 HCPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:927204 HCPLUS
 DN 141:395538
 ED Entered STN: 04 Nov 2004
 TI Preparation of 7-azaindolylglyoxylamides as phosphodiesterase IV inhibitors.
 IN Hoefgen, Norbert; Kuss, Hildegard; Olbrich, Matthias; Egerland, Ute; Rundfeldt, Chris; Steinike, Karin; Schindler, Rudolf
 PA Elbion A.-G., Germany
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 IC ICM C07D-0471/04
 ICS A61K-0031/437; A61P-0035/00
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004094416	A1	20041104	2004WO-EP04339	20040423 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE--10318610	A1	20041111	2003DE-1018610	20030424 <--
	US2004224971	A1	20041111	2004US-0826136	20040416 <--
	CA---2523063	AA	20041104	2004CA-2523063	20040423 <--
	EP---1613627	A1	20060111	2004EP-0729102	20040423 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	2003DE-1018610	A	20030424 <--		
	2004WO-EP04339	W	20040423		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2004094416	ICM	C07D-0471/04
		ICS	A61K-0031/437; A61P-0035/00
		IPCI	C07D0471-04 [ICM, 7]; A61K0031-437 [ICS, 7]; A61P0035-00 [ICS, 7]
		ECLA	C07D471/04+221B+209B <--
	DE--10318610	IPCI	C07D0471-04 [ICM, 7]; A61K0031-437 [ICS, 7]; A61P0019-00 [ICS, 7]; A61P0011-00 [ICS, 7]; A61P0031-00 [ICS, 7]; A61P0035-00 [ICS, 7]
		ECLA	C07D471/04+221B+209B <--
	US2004224971	IPCI	C07D0471-02 [ICM, 7]; C07D0043-02 [ICS, 7]; A61K0031-4745 [ICS, 7]; A61K0031-4439 [ICS, 7]
		NCL	514/300.000
		ECLA	C07D471/04+221B+209B <--
	CA---2523063	IPCI	C07D0471-04 [ICM, 7]; A61P0035-00 [ICS, 7]; A61K0031-437 [ICS, 7]
		ECLA	C07D471/04+221B+209B <--
	EP---1613627	IPCI	C07D0471-04 [ICM, 7]; A61K0031-437 [ICS, 7]; A61P0035-00 [ICS, 7]
		ECLA	C07D471/04+221B+209B <--

OS MARPAT 141:395538

GI



AB Title compds. [I; A = N, N-oxide group; B = C, N, N-oxide group; R1 = (substituted) alkyl, alkenyl; R2 = H, alkyl; R3, R4 = H, alkyl, OH, SH, NH2, NO2, cyano, SO3H, CO2H, alkoxy carbonyl, halo, alkoxy, alkylthio, (substituted) Ph, pyridyl, etc.], were prepared. Thus, N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylic acid

amide in CH₂Cl₂ was treated dropwise with m-chloroperbenzoic acid in HOAc followed by stirring for 7 days to give 9.4% N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylic acid amide. I inhibited phosphodiesterase 4 with IC₅₀'s in the range of 10-10 M to 10-5 M.

ST azaindolylglyoxylamide prep phosphodiesterase inhibitor;
hyperproliferation treatment azaindolylglyoxylamide prep; eosinophil neutrophil connected disease treatment pyridinyl azaindolylglyoxylamide

IT Cell proliferation
(hyperproliferative disorder treatment; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT Drug delivery systems
Human
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT Eosinophil
(treatment of diseases connected with eosinophils; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT Neutrophil
(treatment of diseases connected with neutrophils; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT 785815-36-3P 785815-37-4P 785815-38-5P
785815-39-6P 785815-40-9P 785815-41-0P
785815-42-1P 785815-43-2P 785815-44-3P
785815-45-4P 785815-46-5P 785815-47-6P
785815-48-7P 785815-49-8P 785815-50-1P
785815-51-2P 785815-52-3P 785815-53-4P
785815-54-5P 785815-55-6P 785815-56-7P
785815-57-8P 785815-58-9P 785815-59-0P
785815-60-3P 785815-61-4P 785815-62-5P
785815-63-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT 9036-21-9, Phosphodiesterase IV
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT 418794-42-0 785815-64-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Asta Medica Ag; WO---9809946 A 1998 HCPLUS
- (2) Dresden, A; DE--19818964 A 1999 HCPLUS
- (3) Polymeropoulos, E; WO---0234747 A 2002 HCPLUS
- (4) Rahm; WO---9611929 A 1996 HCPLUS

IT 785815-36-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

RN 785815-36-3 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- α -oxo-, 7-oxide (9CI) (CA INDEX NAME)




L41 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN				
AN	2002:332190	HCAPLUS		
DN	136:340669			
ED	Entered STN: 03 May 2002			
TI	Novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors			
IN	Hoefgen, Norbert; Egerland, Ute; Kronbach, Thomas; Marx, Degenhard; Szelenyi, Stefan; Kuss, Hildegard; Polymeropoulos, Emmanuel			
PA	Arzneimittelwerk Dresden GmbH, Germany			
SO	PCT Int. Appl., 55 pp.			
	CODEN: PIXXD2			
DT	Patent			
LA	German			
IC	ICM C07D-0471/04			
	ICS A61P-0011/00; A61K-0031/40			
CC	28-2 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1			
FAN.CNT 1				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI	WO2002034747	A1	20020502	2001WO-EP12376
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			20011025
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE--10053275	A1	20020502	2000DE-1053275
	CA---2428468	AA	20020502	2001CA-2428468
	AU2002021753	A5	20020506	2002AU-0021753
	EP---1330455	A1	20030730	2001EP-0988718
	EP---1330455	B1	20050803	20011025
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	EE-200300166	A	20030815	2003EE-0000166
	BR2001014903	A	20031014	2001BR-0014903
	JP2004512337	T2	20040422	2002JP-0537738
	NZ---525369	A	20040924	2001NZ-0525369
	AT---301121	E	20050815	2001AT-0988718
	RU---2268887	C2	20060127	2003RU-0115621
	NO2003001722	A	20030414	2003NO-0001722
	BG---107725	A	20040831	2003BG-0107725
	ZA2003003236	A	20030731	2003ZA-0003236
	HR2003000427	A1	20030831	2003HR-0000427

US2004106641	A1	20040603	2003US-0399051	20030617
PRAI 2000DE-1053275	A	20001027		
2000US-244342P	P	20001030		
2001WO-EP12376	W	20011025		
CLASS				
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES				

WO 2002034747	ICM	C07D-0471/04		
	ICS	A61P-0011/00; A61K-0031/40		
	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
	ECLA	C07D471/04+221B+209B		
DE--10053275	IPCI	C07D0471-04 [ICM, 7]; A61K0031-495 [ICS, 7]; A61K0031-505 [ICS, 7]		
	ECLA	C07D471/04+221B+209B		
CA---2428468	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
AU2002021753	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
EP---1330455	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
	ECLA	C07D471/04+221B+209B		
EE-200300166	IPCI	A61K0031-40 [ICM, 7]; A61P0011-00 [ICS, 7]; C07D0471-04 [ICS, 7]		
BR2001014903	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
JP2004512337	IPCI	C07D0471-04 [ICM, 7]; A61K0031-437 [ICS, 7]; A61K0031-444 [ICS, 7]; A61K0031-496 [ICS, 7]; A61K0031-513 [ICS, 7]; A61K0031-5377 [ICS, 7]; A61K0031-541 [ICS, 7]; A61P0001-04 [ICS, 7]; A61P0003-10 [ICS, 7]; A61P0005-48 [ICS, 7]; A61P0007-12 [ICS, 7]; A61P0009-10 [ICS, 7]; A61P0011-00 [ICS, 7]; A61P0011-02 [ICS, 7]; A61P0011-06 [ICS, 7]; A61P0013-00 [ICS, 7]; A61P0013-04 [ICS, 7]; A61P0013-08 [ICS, 7]; A61P0013-12 [ICS, 7]; A61P0015-10 [ICS, 7]; A61P0017-00 [ICS, 7]; A61P0017-06 [ICS, 7]; A61P0019-02 [ICS, 7]; A61P0019-08 [ICS, 7]; A61P0019-10 [ICS, 7]; A61P0025-16 [ICS, 7]; A61P0025-18 [ICS, 7]; A61P0025-28 [ICS, 7]; A61P0025-30 [ICS, 7]; A61P0027-14 [ICS, 7]; A61P0029-00 [ICS, 7]; A61P0031-04 [ICS, 7]; A61P0031-12 [ICS, 7]; A61P0031-18 [ICS, 7]; A61P0033-00 [ICS, 7]; A61P0033-02 [ICS, 7]; A61P0037-02 [ICS, 7]; A61P0037-06 [ICS, 7]; A61P0037-08 [ICS, 7]; A61P0039-02 [ICS, 7]; A61P0043-00 [ICS, 7]		
	FTERM	4C065/AA04; 4C065/BB04; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/JJ01; 4C065/KK01; 4C065/LL01; 4C065/PP12; 4C065/PP15; 4C065/PP16; 4C065/PP17; 4C065/QQ04; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC17; 4C086/BC42; 4C086/BC50; 4C086/BC73; 4C086/BC88; 4C086/CB05; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA01; 4C086/ZA12; 4C086/ZA15; 4C086/ZA16; 4C086/ZA33; 4C086/ZA34; 4C086/ZA45; 4C086/ZA59; 4C086/ZA60; 4C086/ZA66; 4C086/ZA68; 4C086/ZA81; 4C086/ZA84; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB07; 4C086/ZB08; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37; 4C086/ZB38; 4C086/ZC02; 4C086/ZC20; 4C086/ZC35; 4C086/ZC37; 4C086/ZC55		
NZ---525369	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
AT---301121	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40 [ICS, 7]		
	ECLA	C07D471/04+221B+209B		
RU---2268887	IPCI	C07D0471-04 [I,A]; A61P0011-00 [I,A]; A61K0031-40 [I,A]		
NO2003001722	IPCI	C07D0471-04 [ICM, 7]		
BG---107725	IPCI	C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40		

ZA2003003236 IPCI C07D [ICM, 7]; A61P [ICS, 7]; A61K [ICS, 7]
 HR2003000427 IPCI C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40
 [ICS, 7]
 US2004106641 IPCI A61K0031-4745 [ICM, 7]
 NCL 514/300.000
 ECLA C07D471/04+221B+209B
 OS CASREACT 136:340669; MARPAT 136:340669
 GI



AB 7-Azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, uracilyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide which had an IC50 for PDE-4 inhibition of 0.710 μ mol./L.

ST azaindolecarboxamide prepn phosphodiesterase inhibitor

IT Eosinophil
Neutrophil
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 9036-21-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IV; preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 418794-16-8P 418794-19-1P 418794-38-4P
418794-40-8P 418794-42-0P 418794-44-2P
418794-46-4P 418794-47-5P 418794-49-7P
418794-55-5P 418794-57-7P 418794-59-9P
418794-61-3P 418794-63-5P 418794-64-6P
418794-66-8P 418794-73-7P 418794-82-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 61-82-5, 1H-1,2,4-Triazol-3-amine 94-09-7, Ethyl 4-aminobenzoate
109-01-3, N-Methylpiperazine 110-91-8, Morpholine, reactions 111-95-5
150-13-0, 4-Aminobenzoic acid 608-31-1, 2,6-Dichloroaniline 1003-40-3,
4-Aminopyridine hydrochloride 3731-53-1, 4-Aminomethylpyridine
6270-46-8, 5-Amino-6-methyluracil 6315-89-5, 3,4-Dimethoxyaniline
35965-29-8 35965-33-4 39093-93-1, Thiomorpholine S,S-dioxide
55276-24-9, 5-Amino-1,3,6-trimethyluracil 142648-55-3 418794-90-8,
1-(Cyclopropylmethyl)-7-azaindole-3-carboxylic acid 418794-93-1,
1-Isobutyl-7-azaindole-3-carboxylic acid 418794-94-2,
1-Hexyl-7-azaindole-3-carboxylic acid 418794-96-4 418794-98-6
418795-00-3 418795-02-5 418795-04-7, 4-Aminomethyl-3,5-dichloropyridine 418795-06-9 418795-10-5 418795-13-8 418795-15-0
418795-17-2 418795-19-4 418795-20-7 418795-22-9 418795-24-1
418795-26-3 418795-27-4 418795-29-6 418795-30-9 418795-32-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)

IT 418794-92-0P 418795-08-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)

IT 418794-22-6P 418794-24-8P 418794-25-9P 418794-27-1P
 418794-29-3P 418794-30-6P 418794-32-8P 418794-34-0P 418794-36-2P
 418794-51-1P 418794-53-3P 418794-54-4P
 418794-68-0P 418794-70-4P 418794-71-5P
 418794-75-9P 418794-76-0P 418794-78-2P 418794-80-6P
 418794-84-0P 418794-86-2P 418794-88-4P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Fujisawa Pharmaceut Co Ltd; JP--10120681 A 1998 HCPLUS
- (2) Mouaddib, A; SYNTHESIS 2000, 4, P549 HCPLUS
- (3) Smithkline Beecham Plc; WO---9611929 A 1996 HCPLUS
- (4) Sterling Drug Inc; GB---1141949 A 1969 HCPLUS

IT 418794-16-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)

RN 418794-16-8 HCPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-(cyclopropylmethyl)-N-(4-
 pyridinylmethyl)- (9CI) (CA INDEX NAME)



=> b uspatall

FILE 'USPATFULL' ENTERED AT 13:10:30 ON 31 JAN 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:10:30 ON 31 JAN 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn 140 tot

L40 ANSWER 1 OF 4 USPATFULL on STN

AN 2005:293602 USPATFULL

TI Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process


IN for their preparation and pharmaceutical compositions comprising them
 Salom, Barbara, Vedano al Lambro (MI), ITALY
 D'Anello, Matteo, Novate Milanese (MI), ITALY
 Brasca, Maria Gabriella, Milano, ITALY
 Giordano, Patrizia, Cuneo, ITALY
 Martina, Katia, Novara, ITALY
 Angelucci, Francesco, Milano, ITALY
 Brookfield, Frederick Arthur, Wallingford, UNITED KINGDOM
 Trigg, William John, Abingdon, UNITED KINGDOM
 Boyd, Edward Andrew, Reading, UNITED KINGDOM
 Larard, Jonathan Anthony, Pocklington, UNITED KINGDOM
 PA Pharmacia Italia S.p.A., Milano, ITALY (non-U.S. corporation)
 PI US2005256151 A1 20051117
 AI 2004US-0020793 A1 20041223 (11)
 PRAI 2003GB-0030043 20031224
 DT Utility
 FS APPLICATION
 LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300,
 GARDEN CITY, NY, 11530, US
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5529

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 865849-99-6P (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 RN 865849-99-6 USPATFULL
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-benzoyl-N-[(4-fluorophenyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



IT 865849-99-6P (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

L40 ANSWER 2 OF 4 USPATFULL on STN
 AN 2005:241264 USPATFULL
 TI Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
 IN Salom, Barbara, Vedano al Lambro (MI), ITALY
 D'Anello, Matteo, Novate Milanese (MI), ITALY
 Brasca, Maria Gabriella, Milano, ITALY
 Giordano, Patrizia, Cuneo, ITALY
 Martina, Katia, Novara, ITALY
 Tesei, Dania, Ancona, ITALY


Brookfield, Frederick Arthur, Wallingford, UNITED KINGDOM
 Trigg, William John, Abingdon, UNITED KINGDOM
 Boyd, Edward Andrew, Reading, UNITED KINGDOM
 Larard, Jonathan Anthony, Pocklington, UNITED KINGDOM
 PA Pharmacia Italia S.p.A., Milano, ITALY (non-U.S. corporation)
 PI US2005209269 A1 20050922
 AI 2004US-0020794 A1 20041223 (11)
 PRAI 2003GB-0030042 20031224
 DT Utility
 FS APPLICATION
 LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300,
 GARDEN CITY, NY, 11530, US
 CLMN Number of Claims: 31
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 858339-48-7P
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 RN 858339-48-7 USPATFULL
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 858339-48-7P 858339-49-8P 858339-52-3P
 858339-53-4P 858339-57-8P 858339-58-9P
 858339-59-0P 858339-60-3P 858339-65-8P
 858339-66-9P 858339-69-2P 858339-70-5P
 858339-73-8P 858339-74-9P 858339-75-0P
 858339-76-1P 858339-81-8P 858339-82-9P
 858339-85-2P 858339-86-3P 858339-89-6P
 858339-90-9P 858339-91-0P 858339-92-1P
 858339-96-5P 858339-97-6P 858340-00-8P
 858340-01-9P 858340-04-2P 858340-05-3P
 858340-06-4P 858340-07-5P 858340-12-2P
 858340-13-3P 858340-15-5P 858340-16-6P
 858340-17-7P 858340-18-8P 858340-19-9P
 858340-20-2P 858340-85-9P 858340-86-0P
 858340-87-1P
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

L40 ANSWER 3 OF 4 USPATFULL on STN
 AN 2004:286803 USPATFULL
 TI 7-azaindoles and the use thereof as therapeutic agents
 IN Hofgen, Nobert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF
 Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF

Olbrich, Matthias, Moritzburg, GERMANY, FEDERAL REPUBLIC OF
 Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF
 Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF
 Steinike, Karin, Radebul, GERMANY, FEDERAL REPUBLIC OF
 Schindler, Rudolf, Dresden, GERMANY, FEDERAL REPUBLIC OF

PI US2004224971 A1 20041111
 AI 2004US-0826136 A1 20040416 (10)

PRAI DE 2003-10318610 20030424

DT Utility

FS APPLICATION

LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1093

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 785815-36-3P

(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

RN 785815-36-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- α -oxo-, 7-oxide (9CI) (CA INDEX NAME)



IT 785815-36-3P 785815-37-4P 785815-38-5P
 785815-39-6P 785815-40-9P 785815-41-0P
 785815-42-1P 785815-43-2P 785815-44-3P
 785815-45-4P 785815-46-5P 785815-47-6P
 785815-48-7P 785815-49-8P 785815-50-1P
 785815-51-2P 785815-52-3P 785815-53-4P
 785815-54-5P 785815-55-6P 785815-56-7P
 785815-57-8P 785815-58-9P 785815-59-0P
 785815-60-3P 785815-61-4P 785815-62-5P
 785815-63-6P

(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT 418794-42-0 785815-64-7


(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

L40 ANSWER 4 OF 4 USPATFULL on STN

AN 2004:139465 USPATFULL
 TI Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and
 method for producing the same
 IN Hofgen, Norbert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF
 Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF
 Kronbach, Thomas, Radebeul, GERMANY, FEDERAL REPUBLIC OF
 Marx, Degenhard, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
 Szelenyi, Stefan, Schwaig, GERMANY, FEDERAL REPUBLIC OF
 Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF
 Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 PI US2004106641 A1 20040603
 AI 2003US-0399051 A1 20030617 (10)
 2001WO-EP12376 20011025
 PRAI DE 2000-10053275 20001027
 DT Utility
 FS APPLICATION
 LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1214
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to new 7-azaindoles, their use as inhibitors of
 phosphodiesterase 4 and to methods for their synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 418794-16-8P
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)
 RN 418794-16-8 USPATFULL
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-(cyclopropylmethyl)-N-(4-
 pyridinylmethyl)- (9CI) (CA INDEX NAME)



IT 418794-16-8P 418794-38-4P 418794-40-8P
 418794-42-0P 418794-44-2P 418794-46-4P
 418794-47-5P 418794-49-7P 418794-55-5P
 418794-57-7P 418794-59-9P 418794-61-3P
 418794-63-5P 418794-64-6P 418794-66-8P
 418794-73-7P 418794-82-8P
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)
 IT 418794-25-9P 418794-51-1P 418794-53-3P
 418794-54-4P 418794-68-0P 418794-70-4P
 418794-71-5P 418794-84-0P 418794-86-2P
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4
 inhibitors)

=> d his

(FILE 'HOME' ENTERED AT 11:57:09 ON 31 JAN 2006)

FILE 'HCAPLUS' ENTERED AT 11:57:19 ON 31 JAN 2006
 L1 1 US2004224971/PN OR (US2004-826136# OR DE2003-10318610#)/AP, PRN
 E HOFGEN N/AU
 L2 12 E3-4
 E HOEFGEN N/AU
 L3 31 E3-4
 E KUSS H/AU
 L4 51 E3-6, E11
 E OLBRICH M/AU
 L5 24 E3-4, E7
 E EGERLAND U/AU
 L6 20 E3-4
 E RUNDFELDT C/AU
 L7 71 E3-4
 E STEINKE K/AU
 E STEINIKE K/AU
 L8 6 E3-4
 E SCHINDLER R/AU
 L9 775 E3-11
 E SCHINDLER RUD/AU
 L10 28 E4-7
 L11 17 ELBION/CS, PA
 E ELBION/CS, PA
 L12 17 E3-14

FILE 'REGISTRY' ENTERED AT 12:06:35 ON 31 JAN 2006

FILE 'HCAPLUS' ENTERED AT 12:07:37 ON 31 JAN 2006
 L13 TRA L1 1- RN : 31 TERMS

FILE 'REGISTRY' ENTERED AT 12:07:38 ON 31 JAN 2006
 L14 31 SEA L13
 L15 STR
 L16 2 L15
 L17 52 L15 FULL
 SAV TEM BAL136F0/A L17
 L18 30 L17 AND L14

FILE 'HCAPLUS' ENTERED AT 12:27:13 ON 31 JAN 2006
 L19 2 L17
 L20 2 L1-12 AND L19

FILE 'USPATFULL, USPAT2' ENTERED AT 12:31:30 ON 31 JAN 2006
 L21 2 L17
 E HOEFGEN N/AU
 E HOFGEN N/AU

FILE 'HCAOLD' ENTERED AT 12:33:43 ON 31 JAN 2006
 L22 0 L17

FILE 'REGISTRY' ENTERED AT 12:46:26 ON 31 JAN 2006
 L23 STR L15
 L24 0 L23
 L25 98 L23 FULL
 L26 46 L25 NOT L17
 L27 30 L25 AND L14

FILE 'HCAPLUS' ENTERED AT 12:55:05 ON 31 JAN 2006
 L28 3 L26
 L29 1 L28 AND L1-12
 L30 4 L19, L28 AND L1-12, L19-20, L28-29

FILE 'USPATFULL, USPAT2' ENTERED AT 12:58:53 ON 31 JAN 2006
L31 3 L26
L32 4 L21,L31

FILE 'HCAOLD' ENTERED AT 12:59:35 ON 31 JAN 2006
L33 0 L26

FILE 'REGISTRY' ENTERED AT 13:00:51 ON 31 JAN 2006
L34 STR L23
L35 1 L34
L36 101 L34 FULL
L37 3 L36 NOT L25

FILE 'HCAPLUS' ENTERED AT 13:05:47 ON 31 JAN 2006
L38 1 L37

FILE 'USPATFULL, USPAT2' ENTERED AT 13:06:16 ON 31 JAN 2006
L39 1 L37
L40 4 L32,L39

FILE 'HCAPLUS' ENTERED AT 13:07:15 ON 31 JAN 2006
L41 4 L30,L38

FILE 'HCAOLD' ENTERED AT 13:07:34 ON 31 JAN 2006
L42 0 L37

>=